Takara Bio Inc. (4974.T) JPX
Currency In JPY
- General
- Statistics
- Historical Data
- Profile
- Financials
Takara Bio Inc.
Address
7-4-38 Nojihigashi
Kusatsu, 525-0058
Japan
Phone
81 77 565 6920
Website
Sector
Healthcare
Industry
Medical - Specialties
Employees
1779
First IPO Date
December 07, 2004
Key Executives
| Name | Title | Pay | Year Born |
| Tsuyoshi Miyamura | Chief Executive Officer, President & Representative Director | 0 | 1963 |
| Andrew Farmer | Head of Research and Development | 0 | N/A |
| Ikuei Nukaya | Managing Executive Officer & Head of Quality Control Headquarters | 0 | N/A |
| Katsuhiko Kusakabe | Vice President, Executive Officer & Director | 0 | 1961 |
| Akira Kodera | Managing Executive Officer & Head of Sales Division | 0 | N/A |
| Hiroki Tomohisa | Executive Officer | 0 | N/A |
| Kyoko Nakajima | Senior Executive Officer & Head of SCM Division | 0 | N/A |
| Noritaka Nishiwaki | Executive Officer, Deputy GM of Corporate Headquarters & GM of Human Resources Department | 0 | N/A |
| Junichi Mineno | Vice President, Executive Officer & Director | 0 | 1960 |
| Yoh Hamaoka | Vice President, Executive Officer & Director | 0 | 1962 |
Description
Takara Bio Inc., together with its subsidiaries, engages in the businesses of reagents, equipment, contract services, and genetic medicine in Japan, China, the rest of Asia, the United States, Europe, and internationally. The company sells reagents and instruments, including reagents needed for genetic and cellular research, PCR instruments, cellular analysis devices, and in vitro diagnostics for COVID-19 testing. It also provides contract services related to regenerative medicine products and contract services related to gene analysis and testing. In addition, the company is involved in commercialization of its proprietary platform technology for biologics development; development, manufacture, and sale of manufacture ancillary materials, such as RetroNectin that is used in the manufacture of gene therapy product; application for marketing authorization of NY-ESO-1 siTCR gene therapy product; and development of JAK/STAT technology suitable for CAR gene therapy and applied development of CereAAV, a brain-tropic adeno-associated virus vector. It provides its products and services through sales agents or directly to its customers. The company was incorporated in 2002 and is headquartered in Kusatsu, Japan. Takara Bio Inc. is a subsidiary of Takara Holdings Inc.
